ArticleCancer prevention research (Philadelphia, Pa.)2014
Metformin inhibits skin tumor promotion in overweight and obese mice.
Article in Cancer prevention research (Philadelphia, Pa.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 55 citations in OpenAlex.
- Metformin: Old Drug, New Therapeutic Potential in the Skin? A Brief Narrative Review.Advances in therapy · 2025Review
- Metformin: A Dual-Role Player in Cancer Treatment and Prevention.International journal of molecular sciences · 2024Review
- Low-Dose Metformin Treatment Reduces In Vitro Growth of the LL/2 Non-small Cell Lung Cancer Cell Line.Biomedicines · 2022Article
- White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions.Cancer metastasis reviews · 2022Review
- Formulation and Characterization of Metformin-Loaded Ethosomes for Topical Application to Experimentally Induced Skin Cancer in Mice.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Evidence for Involvement of Nonclassical Pathways in the Protection From UV-Induced DNA Damage by Vitamin D-Related Compounds.JBMR plus · 2021Article
- Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice.Biomedicines · 2021Article
- Review
- Phenformin Promotes Keratinocyte Differentiation via the Calcineurin/NFAT Pathway.The Journal of investigative dermatology · 2021Article
- Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells.Cancers · 2020Article
- Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation.PloS one · 2019Article
- Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.American journal of cancer research · 2019Article
- Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.Oncotarget · 2017Article
- Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor RegressionCancer prevention research (Philadelphia, Pa.) · 2017Article
- Metformin targets multiple signaling pathways in cancer.Chinese journal of cancer · 2017Review
- Overexpression of PRAS40(T246A) in the Proliferative Compartment Suppresses mTORC1 Signaling, Keratinocyte Migration, and Skin Tumor Development.The Journal of investigative dermatology · 2016Article
- Obesity and Cancer: An Angiogenic and Inflammatory Link.Microcirculation (New York, N.Y. : 1994) · 2016Review
- Repurposing old drugs to chemoprevention: the case of metformin.Seminars in oncology · 2016Review
- Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.Scientific reports · 2016Article
- When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?Current pharmacology reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet. Rapamycin was included for comparison, and a combination of metformin and rapamycin was also evaluated. Metformin (given in the drinking water) and rapamycin (given topically) inhibited development of both papillomas and squamous cell carcinomas in overweight and obese mice in a dose-dependent manner. A low-dose combination of these two compounds displayed an additive inhibitory effect on tumor development. Metformin treatment also reduced the size of papillomas. Interestingly, all treatments seemed to be at least as effective for inhibiting tumor formation in obese mice, and both metformin and rapamycin were more effective at reducing tumor size in obese mice compared with overweight control mice. The effect of metformin on skin tumor development was associated with a significant reduction in TPA-induced epidermal hyperproliferation. Furthermore, treatment with metformin led to activation of epidermal AMP-activated protein kinase (AMPK) and attenuated signaling through mTOR complex (mTORC)-1 and p70S6K. Combinations of metformin and rapamycin were more effective at blocking epidermal mTORC1 signaling induced by TPA consistent with the greater inhibitory effect on skin tumor promotion. Collectively, the current data demonstrate that metformin given in the drinking water effectively inhibited skin tumor promotion in both overweight and obese mice and that the mechanism involves activation of epidermal AMPK and attenuated signaling downstream of mTORC1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.